Century Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Century Therapeutics Inc Company

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.

Century Therapeutics Inc Info



Ticker SymbolIPSC

Company nameCentury Therapeutics Inc

IPO dateJun 17, 2021

CEODr. Brent Pfeiffenberger, Pharm.D.

Number of employees140

Security typeOrdinary Share

Fiscal year-endJun 17

Address25 N 38Th Street, 11Th Floor

CityPHILADELPHIA

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code19104

Phone12159814000

Websitehttps://www.centurytx.com/

Ticker SymbolIPSC

IPO dateJun 17, 2021

CEODr. Brent Pfeiffenberger, Pharm.D.

Company Executives of Century Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Brent Pfeiffenberger, Pharm.D.

Chairman of the Board, President, Chief Executive Officer

2.04M

-0.02%

Dr. Chad Cowan, Ph.D.

Chief Scientific Officer

992.85K

+331.10%

Mr. Douglas Carr, CPA

Interim Chief Financial Officer

423.31K

-0.06%

Dr. Gregory (Greg) Russotti, Ph.D.

Chief Technology and Manufacturing Officer

379.67K

-0.14%

Dr. Kimberly Lynn Blackwell, M.D.

Independent Director

--

Ms. Daphne E. Quimi, CPA

Independent Director

--

Mr. Timothy P. (Tim) Walbert

Independent Director

--

Dr. Carlo Rizzuto, Ph.D.

Independent Director

--

Dr. Alessandro Riva, M.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Brent Pfeiffenberger, Pharm.D.

Chairman of the Board, President, Chief Executive Officer

2.04M

-0.02%

Dr. Chad Cowan, Ph.D.

Chief Scientific Officer

992.85K

+331.10%

Mr. Douglas Carr, CPA

Interim Chief Financial Officer

423.31K

-0.06%

Dr. Gregory (Greg) Russotti, Ph.D.

Chief Technology and Manufacturing Officer

379.67K

-0.14%

Dr. Kimberly Lynn Blackwell, M.D.

Independent Director

--

Ms. Daphne E. Quimi, CPA

Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Tue, Sep 23

Shareholders

Shareholder Types

Shareholders

Proportion

Bayer AG

14.67%

Versant Ventures

14.08%

Fujifilm Holdings Corp

8.05%

Bain Capital Life Sciences Investors, LLC

6.26%

The Vanguard Group, Inc.

2.44%

Other

54.49%

Shareholders

Proportion

Bayer AG

14.67%

Versant Ventures

14.08%

Fujifilm Holdings Corp

8.05%

Bain Capital Life Sciences Investors, LLC

6.26%

The Vanguard Group, Inc.

2.44%

Other

54.49%

Shareholder Types

Shareholders

Proportion

Corporation

22.72%

Investment Advisor

14.84%

Venture Capital

14.08%

Hedge Fund

9.77%

Individual Investor

5.99%

Investment Advisor/Hedge Fund

2.22%

Research Firm

0.81%

Private Equity

0.03%

Family Office

0.03%

Other

29.51%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

172

36.07M

41.76%

-14.03M

2025Q2

185

65.43M

75.94%

-12.74M

2025Q1

190

67.80M

85.48%

-12.38M

2024Q4

199

74.05M

87.09%

-5.74M

2024Q3

197

77.29M

91.61%

-2.73M

2024Q2

195

76.53M

90.84%

+3.21M

2024Q1

192

59.55M

90.31%

-4.03K

2023Q4

185

53.19M

83.25%

-1.66M

2023Q3

177

52.18M

87.54%

-4.25M

2023Q2

185

53.42M

89.72%

-5.97M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Bayer AG

12.68M

14.67%

--

Apr 15, 2025

Versant Ventures

12.17M

14.08%

--

Apr 15, 2025

Fujifilm Holdings Corp

6.96M

8.05%

--

Apr 15, 2025

Bain Capital Life Sciences Investors, LLC

5.41M

6.26%

--

Jun 30, 2025

The Vanguard Group, Inc.

2.11M

2.44%

-267.41K

-11.25%

Jun 30, 2025

Pfeiffenberger (Brent)

2.04M

2.36%

-488.00

-0.02%

Sep 08, 2025

Renaissance Technologies LLC

2.02M

2.34%

+837.18K

+70.63%

Jun 30, 2025

Dafna Capital Management, LLC

1.70M

1.97%

--

Jun 30, 2025

Casdin Capital, LLC

1.23M

1.42%

-1.98M

-61.77%

Jun 30, 2025

Syncona Portfolio Ltd

1.21M

1.4%

--

Jun 30, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

ProShares Hedge Replication ETF

0%

ProShares UltraPro Russell2000

0%

Schwab U.S. Small-Cap ETF

0%

Schwab U.S. Broad Market ETF

0%

Proshares Ultra Russell 2000

0%

iShares Micro-Cap ETF

0%

iShares Russell 3000 ETF

0%

Global X Russell 2000 Covered Call ETF

0%

iShares Russell 2000 Value ETF

0%

Dimensional US Core Equity 1 ETF

0%

ProShares Hedge Replication ETF

Proportion0%

ProShares UltraPro Russell2000

Proportion0%

Schwab U.S. Small-Cap ETF

Proportion0%

Schwab U.S. Broad Market ETF

Proportion0%

Proshares Ultra Russell 2000

Proportion0%

iShares Micro-Cap ETF

Proportion0%

iShares Russell 3000 ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

iShares Russell 2000 Value ETF

Proportion0%

Dimensional US Core Equity 1 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data